Analysts applauded today's announcement that the FDA will provide a priority review for GlaxoSmithKline's cancer therapy Tykerb [1]. Report [2]
Links:
[1] http://www.fiercebiotech.com/story/gsk-stakes-claim-to-asco-spotlight/2006-05-24
[2] http://www.newratings.com/analyst_news/article_1423362.html